Keros Therapeutics, Inc. current report, 06 January 2023

Full document

Business Context and Reporting Period

Keros Therapeutics, Inc. (KROS) filed a Current Report on Form 8-K dated January 6, 2023. The filing reports the entry into a material definitive agreement regarding the Company's primary office and laboratory space.

Key Financial Metrics

This filing does not contain financial statements, revenue, profit, cash flow, or liquidity metrics. The only financial data disclosed relates to the new lease agreement:

  • Base Rent: Initially fixed at $202,084.66 per month for the full premises.
  • Rent Escalation: Approximately 3% per annum.
  • Lease Term: 8 years, commencing from the Phase A Premises Commencement Date.
  • Property Size: Approximately 35,662 square feet located at 1050 Waltham Street, Lexington, Massachusetts.

Material Changes

The Company entered into a first amendment to its existing lease with Revolution Labs Owner, LLC. Key changes include:

  • Phased Delivery:
    • Phase A: Approximately 31,991 square feet delivered on or before January 4, 2023.
    • Phase B: Approximately 3,671 square feet of vivarium space estimated for delivery on or before May 1, 2023.
  • Rent Commencement:
    • Phase A Rent: Begins on the earlier of eight months after Phase B commencement or 11 months after Phase A commencement.
    • Phase B Rent: Begins eight months after Phase B commencement.
  • Payment Structure: Until Phase B rent commences, the Company pays rent only for Phase A square footage. Upon Phase B commencement, rent covers the entire premises.

Outlook, Risks, and Contingencies

The filing does not provide management commentary on financial outlook, risks, or contingencies beyond the lease terms. The Company noted that the description of the Lease Amendment is qualified by reference to the full agreement, which will be filed as an exhibit to the Form 10-Q for the period ending March 31, 2023.

Investor Verification Checklist

  • Verify the exact Phase B Premises Commencement Date once construction is complete, as this triggers the full rent obligation.
  • Review the full Lease Amendment in the upcoming Form 10-Q (Q1 2023) for details on operating expenses, taxes, and specific cost obligations.
  • Assess the impact of the $202,084.66 monthly rent (once fully active) on the Company's cash burn rate and liquidity position.
  • Confirm the status of the vivarium space delivery, as delays could impact operational timelines.